BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer ; volume:8 ; number:1 ; day:21 ; month:11 ; year:2023 ; pages:1-4 ; date:12.2023
npj vaccines ; 8, Heft 1 (21.11.2023), 1-4, 12.2023
- Urheber
-
Valanparambil, Rajesh M.
Lai, Lilin
Johns, Margaret A.
Davis-Gardner, Meredith
Linderman, Susanne L.
McPherson, Tarrant Oliver
Chang, Andres
Akhtar, Akil
Gamarra, Estefany L. Bocangel
Matia, Hayley
McCook-Veal, Ashley A.
Switchenko, Jeffrey
Nasti, Tahseen H.
Green, Felicia
Saini, Manpreet
Wieland, Andreas
Pinsky, Benjamin A.
Solis, Daniel
Dhodapkar, Madhav V.
Carlisle, Jennifer
Ramalingam, Suresh
Ahmed, Rafi
Suthar, Mehul S.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41541-023-00779-8
- URN
-
urn:nbn:de:101:1-2024021209572242643278
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:33 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Valanparambil, Rajesh M.
- Lai, Lilin
- Johns, Margaret A.
- Davis-Gardner, Meredith
- Linderman, Susanne L.
- McPherson, Tarrant Oliver
- Chang, Andres
- Akhtar, Akil
- Gamarra, Estefany L. Bocangel
- Matia, Hayley
- McCook-Veal, Ashley A.
- Switchenko, Jeffrey
- Nasti, Tahseen H.
- Green, Felicia
- Saini, Manpreet
- Wieland, Andreas
- Pinsky, Benjamin A.
- Solis, Daniel
- Dhodapkar, Madhav V.
- Carlisle, Jennifer
- Ramalingam, Suresh
- Ahmed, Rafi
- Suthar, Mehul S.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine
Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera
Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia
Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome
Bivalent single domain antibody constructs for effective neutralization of Venezuelan equine encephalitis
Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19
Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
Limited cross-variant neutralization after primary Omicron infection: consideration for a variant-containing booster
Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant
Cost-Effectiveness of Bivalent, Quadrivalent, and Nonavalent HPV Vaccination in South Africa
Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine
Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera
Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia
Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome
Bivalent single domain antibody constructs for effective neutralization of Venezuelan equine encephalitis
Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19
Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
Limited cross-variant neutralization after primary Omicron infection: consideration for a variant-containing booster
Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant
Cost-Effectiveness of Bivalent, Quadrivalent, and Nonavalent HPV Vaccination in South Africa
Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine
Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera
Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia
Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome
Bivalent single domain antibody constructs for effective neutralization of Venezuelan equine encephalitis
Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19
Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
Limited cross-variant neutralization after primary Omicron infection: consideration for a variant-containing booster
Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant